← 產業報告目錄

Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, PCR, NGS), Disease (Hepatitis, HIV, HAI, TB, Flu, Syphilis), End User (Labs) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-09-05頁數 447報告編號 MD3088

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The infectious disease diagnostics market is projected to reach USD 42.20 billion by 2030 from USD 26.58 billion in 2025, at a CAGR of 9.7% during the forecast period. The factors driving the market growth include the increasing emphasis on decentralized diagnostics and the rising demand for CLIA-waived point-of-care (PoC) tests. These trends have significantly contributed to the widespread adoption of PoC technologies. The need for efficient healthcare delivery primarily fuels the shift towards decentralized PoC testing. By relocating diagnostic testing to point-of-care settings, healthcare providers can perform diagnostics directly at the patient's side, minimizing the time between sample collection and results. By type of testing, the PoC testing segment is expected to grow at the highest CAGR during the forecast period. By type of testing, the infectious disease diagnostics market is segmented into laboratory and PoC testing. The PoC testing segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is attributed to the increasing investments from key companies, with a strong emphasis on innovation through product launches & strategic acquisitions. PoC testing offers several advantages over traditional laboratory testing, particularly in clinical & hospital settings. A key benefit of PoC testing is its rapid turnaround time, enabling enhanced diagnostic decisions. Moreover, PoC testing typically requires smaller sample volumes, making it less invasive and efficient. By technology, the DNA sequencing & next-generation sequencing segment is expected to grow at the highest CAGR during the forecast period. The infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies. The DNA sequencing & next-generation sequencing segment is projected to register the highest CAGR during the forecast period. DNA sequencing is a user-friendly platform that is easily implemented in clinical settings to deliver rapid results. Its ability to analyze genetic material has expanded its potential across applications, including personalized medicine, cancer research, and drug discovery. Moreover, advancements in sequencing technologies, broadening applications across multiple domains, and the rising demand for personalized medicine are key factors expected to support the growth of this market segment in the coming years. By region, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, which has been attributed to rising healthcare spending and the uptake of advanced diagnostics. Additional growth drivers include the rising incidence & prevalence of infectious diseases, modernization of healthcare infrastructure, and the increasing adoption of advanced diagnostic technologies, particularly in rural areas. The break-up of the profile of primary participants in the infectious disease diagnostics market: • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30% • By Designation: C-level - 27%, D-level - 18%, and Others - 55% • By Region: North America - 51%, Europe - 21%, the Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa- 4% The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Revvity, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Seegene Inc. (South Korea), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), OraSure Technologies, Inc. (US), Co-Diagnostics, Inc. (US), SD Biosensor, INC. (South Korea), BIOSYNEX SA (France), Trinity Biotech (Ireland), Bruker (US), Genetic Signatures Ltd. (Australia), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Unijogen Oy (Finland), Vela Diagnostics (Singapore), and Molbio Diagnostics Limited (India). Research Coverage: This research report categorizes the infectious disease diagnostics market by product & service (reagents, kits, and consumables, instruments, and software & services), by type of testing (laboratory testing, PoC testing), by disease type (hepatitis, HIV, hospital-acquired infections, mosquito-borne diseases, HPV, Chlamydia trachomatis, Neisseria gonorrhea, tuberculosis, influenza, syphilis, and other infectious diseases), by sample type (blood, serum, and plasma, urine, and other sample types), by technology (immunodiagnostics, polymerase chain reaction, clinical microbiology, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarray, and other technologies), by clinical application (diagnostics and screening), by end user (diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users), and region (North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the infectious disease diagnostics market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent infectious disease diagnostics market developments. This report covers the competitive analysis of upcoming startups in the infectious disease diagnostics market ecosystem. Reasons to Buy this Report: The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (Rising prevalence of infectious diseases, rising focus on R&D and funding investments for infectious disease diagnostic products, adoption of innovative & advanced technologies for infectious disease diagnosis, gradual shift from centralized laboratories to decentralized POC testing centers), opportunities (high growth potential of emerging economies), restraints (unfavorable reimbursements), and challenges (stringent regulatory guidelines for ivd products, operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market. • Market Development: Comprehensive information about lucrative markets – the report analyses the infectious disease diagnostics market across varied regions. • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), and Thermo Fisher Scientific Inc. (US), among others, in the infectious disease diagnostics market.
目錄 Table of Contents
1 INTRODUCTION 39 1.1 STUDY OBJECTIVES 39 1.2 MARKET DEFINITION 39 1.3 MARKET SCOPE 40 1.3.1 MARKETS COVERED & REGIONAL SCOPE 40 1.3.2 INCLUSIONS & EXCLUSIONS 41 1.3.3 YEARS CONSIDERED 42 1.3.4 CURRENCY CONSIDERED 42 1.4 KEY STAKEHOLDERS 42 1.5 SUMMARY OF CHANGES 43 2 RESEARCH METHODOLOGY 44 2.1 RESEARCH DATA 44 2.2 RESEARCH APPROACH 44 2.2.1 SECONDARY DATA 45 2.2.1.1 Key secondary sources 45 2.2.1.2 Key data from secondary sources 46 2.2.2 PRIMARY DATA 47 2.2.2.1 Primary sources 47 2.2.2.2 Key data from primary sources 48 2.2.2.3 Key industry insights 49 2.2.2.4 Breakdown of primary interviews 50 2.3 MARKET SIZE ESTIMATION 50 2.3.1 BOTTOM-UP APPROACH 51 2.3.1.1 Approach 1: Company revenue estimation approach 51 2.3.1.2 Approach 2: Presentations of companies and primary interviews 52 2.3.1.3 Growth forecast 52 2.3.1.4 CAGR projections 52 2.3.2 TOP-DOWN APPROACH 53 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 55 2.5 MARKET SHARE ASSESSMENT 55 2.6 RESEARCH ASSUMPTIONS 56 2.6.1 PARAMETRIC ASSUMPTIONS 56 2.7 RESEARCH LIMITATIONS 56 2.8 RISK ASSESSMENT 57 3 EXECUTIVE SUMMARY 58   4 PREMIUM INSIGHTS 64 4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW 64 4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 65 4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION) 65 4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 66 4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION) 66 4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 67 4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION) 67 4.8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 68 4.9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68 5 MARKET OVERVIEW 69 5.1 INTRODUCTION 69 5.2 MARKET DYNAMICS 69 5.2.1 DRIVERS 70 5.2.1.1 Rising prevalence of infectious diseases 70 5.2.1.2 Rising focus on R&D and funding investments for infectious disease diagnostic products 71 5.2.1.3 Adoption of innovative & advanced technologies for infectious disease diagnosis 72 5.2.1.4 Gradual shift from centralized laboratories to decentralized PoC testing centers 73 5.2.2 RESTRAINTS 74 5.2.2.1 Unfavorable reimbursements 74 5.2.3 OPPORTUNITIES 74 5.2.3.1 High growth potential of emerging economies 74 5.2.4 CHALLENGES 76 5.2.4.1 Stringent regulatory guidelines for IVD products 76 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians 76 5.3 PRICING ANALYSIS 77 5.3.1 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023−2025 77 5.3.2 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023−2025 77 5.3.3 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023−2025 78 5.4 PATENT ANALYSIS 79 5.4.1 LIST OF MAJOR PATENTS 80 5.5 VALUE CHAIN ANALYSIS 81 5.6 SUPPLY CHAIN ANALYSIS 82 5.7 TRADE ANALYSIS 83 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 83 5.7.2 IMPORT DATA (HS CODE 3822) 84 5.7.3 EXPORT DATA (HS CODE 3822) 84 5.8 ECOSYSTEM ANALYSIS 85 5.8.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 85 5.9 PORTER’S FIVE FORCES ANALYSIS 86 5.9.1 THREAT OF NEW ENTRANTS 87 5.9.2 THREAT OF SUBSTITUTES 87 5.9.3 BARGAINING POWER OF BUYERS 87 5.9.4 BARGAINING POWER OF SUPPLIERS 87 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 88 5.10 REGULATORY LANDSCAPE 88 5.10.1 REGULATORY FRAMEWORK 88 5.10.1.1 North America 88 5.10.1.1.1 US 88 5.10.1.1.2 Canada 88 5.10.1.2 Europe 88 5.10.1.2.1 Germany 89 5.10.1.2.2 UK 89 5.10.1.2.3 France 90 5.10.1.2.4 Italy 90 5.10.1.3 Asia Pacific 90 5.10.1.3.1 China 90 5.10.1.3.2 Japan 90 5.10.1.3.3 India 91 5.10.1.4 Latin America 91 5.10.1.4.1 Brazil 91 5.10.1.4.2 Mexico 92 5.10.1.5 Middle East 92 5.10.1.5.1 Africa 92 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 5.11 TECHNOLOGY ANALYSIS 94 5.11.1 KEY TECHNOLOGIES 94 5.11.1.1 Immunodiagnostics 94 5.11.2 COMPLEMENTARY TECHNOLOGIES 95 5.11.2.1 Polymerase Chain Reaction (PCR) 95 5.11.3 ADJACENT TECHNOLOGIES 96 5.11.3.1 Next-generation Sequencing (NGS) 96 5.12 KEY CONFERENCES & EVENTS, 2025–2026 97 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 98 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 98 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 99 5.14.2 BUYING CRITERIA 99 5.15 INVESTMENT & FUNDING SCENARIO 100 5.16 CASE STUDY ANALYSIS 101 5.16.1 CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT 101 5.16.2 CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS 101 5.16.3 CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS 102 5.17 IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET 102 5.17.1 INTRODUCTION 102 5.17.2 MARKET POTENTIAL OF AI 103 5.17.3 AI-USE CASES 103 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE 104 5.17.5 FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 104 5.18 TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET 105 5.18.1 INTRODUCTION 105 5.18.2 KEY TARIFF RATES 105 5.18.3 PRICE IMPACT ANALYSIS 106 5.18.4 KEY IMPACT ON COUNTRY/REGION 106 5.18.4.1 North America 106 5.18.4.2 Europe 106 5.18.4.3 Asia Pacific 107 5.18.5 IMPACT ON END-USE INDUSTRIES 107 5.18.5.1 Diagnostic laboratories 107 5.18.5.2 Hospitals & clinics 107 5.18.5.3 Academic research institutes 107 6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 108 6.1 INTRODUCTION 109 6.2 REAGENTS, KITS, AND CONSUMABLES 109 6.2.1 RECURRENT PURCHASE TO PROPEL MARKET 109 6.3 INSTRUMENTS 114 6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET 114 6.4 SOFTWARE & SERVICES 118 6.4.1 INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH 118   7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING 122 7.1 INTRODUCTION 123 7.2 LABORATORY TESTING 123 7.2.1 HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE 123 7.3 POC TESTING 126 7.3.1 RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET 126 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE 130 8.1 INTRODUCTION 131 8.2 BLOOD, SERUM, AND PLASMA 131 8.2.1 HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET 131 8.3 URINE 134 8.3.1 NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND 134 8.4 OTHER SAMPLE TYPES 137 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE 140 9.1 INTRODUCTION 141 9.2 HEPATITIS 142 9.2.1 HEPATITIS B 146 9.2.1.1 Highly contagious infection and requirement for regular monitoring to fuel market 146 9.2.2 HEPATITIS C 149 9.2.2.1 Rising incidence of chronic HCV and supportive government initiatives to drive market 149 9.2.3 OTHER HEPATITIS DISEASES 151 9.3 HIV 154 9.3.1 INCREASING PREVALENCE OF AIDS TO BOOST DEMAND 154 9.4 HOSPITAL-ACQUIRED INFECTIONS 157 9.4.1 RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET 157 9.5 MOSQUITO-BORNE DISEASES 160 9.5.1 RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET 160 9.6 HPV 164 9.6.1 RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND 164 9.7 CHLAMYDIA TRACHOMATIS 166 9.7.1 INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE 166 9.8 NEISSERIA GONORRHEA 169 9.8.1 RISING INCIDENCE OF GONORRHEA TO FUEL MARKET 169 9.9 TUBERCULOSIS 172 9.9.1 INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET 172   9.10 INFLUENZA 175 9.10.1 INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET 175 9.11 SYPHILIS 178 9.11.1 IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE 178 9.12 OTHER INFECTIOUS DISEASES 181 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 184 10.1 INTRODUCTION 185 10.2 IMMUNODIAGNOSTICS 185 10.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET 185 10.3 CLINICAL MICROBIOLOGY 189 10.3.1 RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND 189 10.4 POLYMERASE CHAIN REACTION 192 10.4.1 CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE 192 10.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 195 10.5.1 ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE 195 10.6 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 197 10.6.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET 197 10.7 DNA MICROARRAY 200 10.7.1 HIGH INSTRUMENT COSTS TO LIMIT MARKET 200 10.8 OTHER TECHNOLOGIES 203 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION 206 11.1 INTRODUCTION 207 11.2 DIAGNOSTICS 207 11.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET 207 11.3 SCREENING 210 11.3.1 GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET 210 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 214 12.1 INTRODUCTION 215 12.2 DIAGNOSTIC LABORATORIES 215 12.2.1 ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET 215 12.3 HOSPITALS & CLINICS 218 12.3.1 IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET 218 12.4 ACADEMIC RESEARCH INSTITUTES 221 12.4.1 INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET 221 12.5 OTHER END USERS 224 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION 227 13.1 INTRODUCTION 228 13.2 NORTH AMERICA 228 13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 230 13.2.2 US 235 13.2.2.1 High healthcare expenditure to drive market 235 13.2.3 CANADA 239 13.2.3.1 Supportive government initiatives for infectious disease prevention to fuel market 239 13.3 EUROPE 243 13.3.1 EUROPE: MACROECONOMIC OUTLOOK 244 13.3.2 GERMANY 248 13.3.2.1 High adoption of advanced technologies to propel market 248 13.3.3 UK 253 13.3.3.1 Increasing number of diagnostic centers to fuel uptake 253 13.3.4 FRANCE 257 13.3.4.1 Rising expenditure on life sciences R&D to drive market 257 13.3.5 ITALY 261 13.3.5.1 Rising incidence of chronic diseases to boost demand 261 13.3.6 SPAIN 265 13.3.6.1 High prevalence of HIV and consolidation of diagnostic laboratories to drive market 265 13.3.7 REST OF EUROPE 269 13.4 ASIA PACIFIC 273 13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 274 13.4.2 CHINA 279 13.4.2.1 Increasing burden of hepatitis B virus cases and growing government focus on health surveillance to drive market 279 13.4.3 JAPAN 283 13.4.3.1 Presence of established healthcare system and universal reimbursement policies to fuel uptake 283 13.4.4 INDIA 288 13.4.4.1 High prevalence of TB & HIV to propel market 288 13.4.5 REST OF ASIA PACIFIC 292 13.5 LATIN AMERICA 297 13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 298 13.5.2 BRAZIL 302 13.5.2.1 Rising focus on initiating public-private investments for healthcare improvement to fuel uptake 302 13.5.3 MEXICO 306 13.5.3.1 Improving accessibility & affordability of healthcare services to support market growth 306 13.5.4 REST OF LATIN AMERICA 310 13.6 MIDDLE EAST & AFRICA 314 13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 315 13.6.2 KINGDOM OF SAUDI ARABIA (KSA) 319 13.6.2.1 Integration of digital health systems and improvements in healthcare infrastructure to fuel market 319 13.6.3 UNITED ARAB EMIRATES (UAE) 323 13.6.3.1 Rising requirement of high-quality healthcare services to support market growth 323 13.6.4 REST OF MIDDLE EAST & AFRICA 327 14 COMPETITIVE LANDSCAPE 332 14.1 INTRODUCTION 332 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 332 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 332 14.3 REVENUE SHARE ANALYSIS, 2022−2024 334 14.4 MARKET SHARE ANALYSIS, 2024 335 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 337 14.5.1 STARS 337 14.5.2 EMERGING LEADERS 337 14.5.3 PERVASIVE PLAYERS 337 14.5.4 PARTICIPANTS 337 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 339 14.5.5.1 Company footprint 339 14.5.5.2 Region footprint 339 14.5.5.3 Product & Service footprint 340 14.5.5.4 Type of testing footprint 340 14.5.5.5 Sample type footprint 341 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 341 14.6.1 PROGRESSIVE COMPANIES 341 14.6.2 RESPONSIVE COMPANIES 341 14.6.3 DYNAMIC COMPANIES 341 14.6.4 STARTING BLOCKS 342 14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 343 14.6.5.1 Detailed list of key startups/SMEs 343 14.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 343 14.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 344 14.7 COMPANY VALUATION & FINANCIAL METRICS 344 14.7.1 FINANCIAL METRICS 344 14.7.2 COMPANY VALUATION 345 14.8 BRAND/PRODUCT COMPARISON 346 14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 346 14.9 COMPETITIVE SCENARIO 346 14.9.1 PRODUCT/SERVICES LAUNCHES & APPROVALS 346 14.9.2 DEALS 347 14.9.3 EXPANSIONS 348 15 COMPANY PROFILES 349 15.1 KEY PLAYERS 349 15.1.1 F. HOFFMANN-LA ROCHE LTD. 349 15.1.1.1 Business overview 349 15.1.1.2 Products/Services offered 350 15.1.1.3 Recent developments 353 15.1.1.3.1 Product/Service launches & approvals 353 15.1.1.3.2 Deals 355 15.1.1.3.3 Expansions 355 15.1.1.4 MnM view 356 15.1.1.4.1 Key strengths 356 15.1.1.4.2 Strategic choices 356 15.1.1.4.3 Weaknesses & competitive threats 356 15.1.2 ABBOTT 357 15.1.2.1 Business overview 357 15.1.2.2 Products/Services offered 358 15.1.2.3 Recent developments 360 15.1.2.3.1 Product/Service launches & approvals 360 15.1.2.3.2 Deals 361 15.1.2.4 MnM view 361 15.1.2.4.1 Key strengths 361 15.1.2.4.2 Strategic choices 361 15.1.2.4.3 Weaknesses & competitive threats 361 15.1.3 DANAHER CORPORATION 362 15.1.3.1 Business overview 362 15.1.3.2 Products/Services offered 363 15.1.3.3 Recent developments 365 15.1.3.3.1 Product/Service launches & approvals 365 15.1.3.3.2 Deals 366 15.1.3.3.3 Expansions 367 15.1.3.4 MnM view 367 15.1.3.4.1 Key strengths 367 15.1.3.4.2 Strategic choices 367 15.1.3.4.3 Weaknesses & competitive threats 367   15.1.4 BIOMÉRIEUX 368 15.1.4.1 Business overview 368 15.1.4.2 Products/Services offered 369 15.1.4.3 Recent developments 373 15.1.4.3.1 Product/Service launches & approvals 373 15.1.4.3.2 Deals 375 15.1.4.4 MnM view 376 15.1.4.4.1 Key strengths 376 15.1.4.4.2 Strategic choices 376 15.1.4.4.3 Weaknesses & competitive threats 376 15.1.5 THERMO FISHER SCIENTIFIC INC. 377 15.1.5.1 Business overview 377 15.1.5.2 Products/Services offered 378 15.1.5.3 Recent developments 380 15.1.5.3.1 Product/Service launches & approvals 380 15.1.5.3.2 Deals 381 15.1.5.4 MnM view 382 15.1.5.4.1 Key strengths 382 15.1.5.4.2 Strategic choices 382 15.1.5.4.3 Weaknesses & competitive threats 382 15.1.6 SIEMENS HEALTHINEERS AG 383 15.1.6.1 Business overview 383 15.1.6.2 Products/Services offered 384 15.1.6.3 Recent developments 386 15.1.6.3.1 Product/Service launches & approvals 386 15.1.6.3.2 Deals 386 15.1.6.3.3 Expansions 387 15.1.7 HOLOGIC, INC. 388 15.1.7.1 Business overview 388 15.1.7.2 Products/Services offered 389 15.1.7.3 Recent developments 390 15.1.7.3.1 Product/Service launches & approvals 390 15.1.7.3.2 Deals 391 15.1.8 BECTON, DICKINSON AND COMPANY (BD) 392 15.1.8.1 Business overview 392 15.1.8.2 Products/Services offered 393 15.1.8.3 Recent developments 396 15.1.8.3.1 Product/Service launches & approvals 396 15.1.8.3.2 Deals 397 15.1.8.3.3 Expansions 398   15.1.9 REVVITY, INC. 399 15.1.9.1 Business overview 399 15.1.9.2 Products/Services offered 400 15.1.9.3 Recent developments 402 15.1.9.3.1 Product/Service launches & approvals 402 15.1.10 QIAGEN N.V. 403 15.1.10.1 Business overview 403 15.1.10.2 Products/Services offered 404 15.1.10.3 Recent developments 406 15.1.10.3.1 Product/Service launches & approvals 406 15.1.10.3.2 Deals 408 15.1.10.3.3 Expansions 408 15.1.11 SEEGENE INC. 409 15.1.11.1 Business overview 409 15.1.11.2 Products/Services offered 410 15.1.11.3 Recent developments 411 15.1.11.3.1 Product/Service launches & approvals 411 15.1.11.3.2 Deals 412 15.1.11.3.3 Expansions 413 15.2 OTHER PLAYERS 414 15.2.1 QUIDELORTHO CORPORATION 414 15.2.2 GRIFOLS, S.A. 416 15.2.3 DIASORIN S.P.A 417 15.2.4 BIO-RAD LABORATORIES, INC. 419 15.2.5 SYSMEX CORPORATION 421 15.2.6 ORASURE TECHNOLOGIES, INC. 422 15.2.7 CO-DIAGNOSTICS, INC. 423 15.2.8 SD BIOSENSOR, INC. 424 15.2.9 BIOSYNEX SA 425 15.2.10 TRINITY BIOTECH 427 15.2.11 BRUKER (ELITECHGROUP) 428 15.2.12 GENETIC SIGNATURES 430 15.2.13 EPITOPE DIAGNOSTICS, INC. 430 15.2.14 TRIVITRON HEALTHCARE 431 15.2.15 MERIL LIFE SCIENCES PVT. LTD. 432 15.2.16 INBIOS INTERNATIONAL, INC. 433 15.2.17 UNIOGEN OY 434 15.2.18 VELA DIAGNOSTICS 435 15.2.19 MOLBIO DIAGNOSTICS LIMITED 436   16 APPENDIX 438 16.1 DISCUSSION GUIDE 438 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 443 16.3 CUSTOMIZATION OPTIONS 445 16.4 RELATED REPORTS 445 16.5 AUTHOR DETAILS 446
圖表清單 List of Tables & Figures
TABLE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 41 TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 48 TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 57 TABLE 4 REGIONAL HIV DATA, 2024 71 TABLE 5 INDICATIVE SELLING PRICING TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2023–2025 77 TABLE 6 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER, 2023–2025 77 TABLE 7 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025 78 TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS 80 TABLE 9 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 84 TABLE 10 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 84 TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 85 TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 87 TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE 89 TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 91 TABLE 17 ASIA PACIFIC: LIST OF KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 97 TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%) 99 TABLE 22 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY RANK 100 TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE 104 TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 105 TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION)T 109 TABLE 26 KEY REAGENTS, KITS, AND CONSUMABLES CURRENTLY AVAILABLE 111 TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 29 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 30 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 31 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 32 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 33 KEY INSTRUMENTS CURRENTLY AVAILABLE 115 TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 35 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 36 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 38 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 39 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE 118 TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 42 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 43 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 44 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 45 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 46 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 123 TABLE 48 KEY LABORATORY TEST TYPES CURRENTLY AVAILABLE 124 TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 50 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 51 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 52 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 53 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 54 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 55 KEY POC TESTING TYPES CURRENTLY AVAILABLE 127 TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 58 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 59 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 60 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 61 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 131 TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 64 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 65 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 66 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 67 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 68 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 71 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 72 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 73 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 74 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 75 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 77 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 78 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 79 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 80 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 81 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 141 TABLE 82 KEY HEPATITIS TESTING PRODUCTS CURRENTLY AVAILABLE 143 TABLE 83 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 84 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 86 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 87 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 88 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 89 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 90 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 91 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 92 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 93 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 94 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 95 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 96 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 97 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 98 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 99 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 100 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 101 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 102 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 103 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 104 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 105 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 106 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 107 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 108 KEY HIV TESTING PRODUCTS CURRENTLY AVAILABLE 154 TABLE 109 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 110 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 111 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 113 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 114 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 115 KEY HAI TESTING PRODUCTS CURRENTLY AVAILABLE 158 TABLE 116 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 117 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 118 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 119 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 120 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 121 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 122 KEY DENGUE-TESTING PRODUCTS CURRENTLY AVAILABLE 161 TABLE 123 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 124 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 125 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, 2023–2030 (USD MILLION) 162 TABLE 126 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 127 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 128 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 129 KEY HPV TESTING PRODUCTS CURRENTLY AVAILABLE 164 TABLE 130 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 131 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 132 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 133 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 136 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS CURRENTLY AVAILABLE 167 TABLE 137 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 138 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 139 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 140 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 141 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 142 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 143 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 144 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 145 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 146 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 147 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 148 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 149 KEY TUBERCULOSIS TESTING PRODUCTS CURRENTLY AVAILABLE 173 TABLE 150 GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (IN MILLIONS) 173 TABLE 151 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 152 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 153 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 154 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 155 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 156 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 157 KEY INFLUENZA TESTING PRODUCTS CURRENTLY AVAILABLE 176 TABLE 158 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 159 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 160 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 161 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 162 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 163 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 164 KEY SYPHILIS TESTING PRODUCTS CURRENTLY AVAILABLE 179 TABLE 165 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 166 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 167 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 168 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 169 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 170 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 171 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 172 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 173 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 174 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 175 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 176 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 177 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 185 TABLE 178 KEY IMMUNODIAGNOSTICS-BASED PRODUCTS CURRENTLY AVAILABLE 186 TABLE 179 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 187 TABLE 180 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 181 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 182 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 183 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 184 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 185 KEY CLINICAL MICROBIOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE 189 TABLE 186 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 187 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 188 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 189 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 190 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 191 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 191 TABLE 192 KEY POLYMERASE CHAIN REACTION-BASED PRODUCTS CURRENTLY AVAILABLE 192 TABLE 193 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 194 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 195 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 196 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 197 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 198 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 199 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE 195 TABLE 200 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 201 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 202 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 203 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 204 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 205 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 206 KEY DNA SEQUENCING & NEXT-GENERATION SEQUENCING-BASED PRODUCTS CURRENTLY AVAILABLE 198 TABLE 207 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 208 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 209 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, 2023–2030 (USD MILLION) 199 TABLE 210 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 211 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 212 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 213 KEY DNA MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE 201 TABLE 214 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 215 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 216 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 217 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 218 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 219 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 220 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 221 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 222 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 223 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 224 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 225 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 205 TABLE 226 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 207 TABLE 227 KEY DIAGNOSTICS PRODUCTS CURRENTLY AVAILABLE 208 TABLE 228 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 208 TABLE 229 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 230 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 231 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 232 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 233 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 234 KEY SCREENING PRODUCTS CURRENTLY AVAILABLE 211 TABLE 235 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023–2030 (USD MILLION) 211 TABLE 236 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 237 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 238 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 239 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 212 TABLE 240 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 241 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 242 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 243 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 244 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 245 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 246 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 217 TABLE 247 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 248 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION) 219 TABLE 249 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 250 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 251 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 252 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 253 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 254 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 222 TABLE 255 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 256 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 257 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 258 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 259 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 260 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 224 TABLE 261 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 262 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 263 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 225 TABLE 264 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 265 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 266 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 228 TABLE 267 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 231 TABLE 268 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 231 TABLE 269 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 231 TABLE 270 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 232 TABLE 271 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 232 TABLE 272 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 273 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 233 TABLE 274 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 275 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 276 NORTH AMERICA: MACROECONOMIC INDICATORS 234 TABLE 277 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 236 TABLE 278 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 236 TABLE 279 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 236 TABLE 280 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 237 TABLE 281 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 282 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 238 TABLE 283 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 238 TABLE 284 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 239 TABLE 285 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 240 TABLE 286 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 240 TABLE 287 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 241 TABLE 288 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 241 TABLE 289 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 290 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 242 TABLE 291 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 292 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 243 TABLE 293 EUROPE: MACROECONOMIC INDICATORS 244 TABLE 294 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 295 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 245 TABLE 296 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 245 TABLE 297 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 246 TABLE 298 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 246 TABLE 299 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 300 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 247 TABLE 301 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 248 TABLE 302 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 303 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 249 TABLE 304 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 250 TABLE 305 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 250 TABLE 306 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 251 TABLE 307 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 308 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 252 TABLE 309 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 252 TABLE 310 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 253 TABLE 311 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 254 TABLE 312 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 254 TABLE 313 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 255 TABLE 314 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 255 TABLE 315 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 316 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 256 TABLE 317 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 318 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 257 TABLE 319 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 258 TABLE 320 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 258 TABLE 321 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 258 TABLE 322 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 259 TABLE 323 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 324 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 260 TABLE 325 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 326 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 261 TABLE 327 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 262 TABLE 328 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 262 TABLE 329 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 262 TABLE 330 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 263 TABLE 331 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 332 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 264 TABLE 333 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 334 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 265 TABLE 335 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 266 TABLE 336 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 266 TABLE 337 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 266 TABLE 338 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 267 TABLE 339 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 340 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 268 TABLE 341 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 342 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 343 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%) 269 TABLE 344 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 270 TABLE 345 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 270 TABLE 346 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 270 TABLE 347 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 271 TABLE 348 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 349 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 272 TABLE 350 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 272 TABLE 351 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 273 TABLE 352 ASIA PACIFIC: MACROECONOMIC INDICATORS 275 TABLE 353 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 275 TABLE 354 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 275 TABLE 355 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 276 TABLE 356 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 276 TABLE 357 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 277 TABLE 358 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 277 TABLE 359 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 278 TABLE 360 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 361 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 279 TABLE 362 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 280 TABLE 363 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 280 TABLE 364 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 281 TABLE 365 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 281 TABLE 366 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 367 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 282 TABLE 368 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 283 TABLE 369 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 370 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 284 TABLE 371 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 285 TABLE 372 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 285 TABLE 373 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 286 TABLE 374 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 286 TABLE 375 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 287 TABLE 376 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 287 TABLE 377 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 288 TABLE 378 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 289 TABLE 379 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 289 TABLE 380 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 290 TABLE 381 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 290 TABLE 382 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 291 TABLE 383 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 291 TABLE 384 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 292 TABLE 385 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 292 TABLE 386 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 293 TABLE 387 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 294 TABLE 388 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 294 TABLE 389 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 295 TABLE 390 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 295 TABLE 391 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 296 TABLE 392 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 296 TABLE 393 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 297 TABLE 394 LATIN AMERICA: MACROECONOMIC INDICATORS 298 TABLE 395 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 298 TABLE 396 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 299 TABLE 397 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 299 TABLE 398 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 299 TABLE 399 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 300 TABLE 400 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 401 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 301 TABLE 402 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 301 TABLE 403 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 302 TABLE 404 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 303 TABLE 405 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 303 TABLE 406 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 303 TABLE 407 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 304 TABLE 408 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 304 TABLE 409 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 305 TABLE 410 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 305 TABLE 411 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 306 TABLE 412 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 307 TABLE 413 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 307 TABLE 414 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 307 TABLE 415 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 308 TABLE 416 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 308 TABLE 417 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 309 TABLE 418 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 309 TABLE 419 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 310 TABLE 420 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 311 TABLE 421 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 311 TABLE 422 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 312 TABLE 423 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 312 TABLE 424 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 313 TABLE 425 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 313 TABLE 426 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 313 TABLE 427 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 314 TABLE 428 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 315 TABLE 429 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 316 TABLE 430 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 316 TABLE 431 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 316 TABLE 432 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 317 TABLE 433 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 317 TABLE 434 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 318 TABLE 435 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 318 TABLE 436 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 319 TABLE 437 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 319 TABLE 438 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 320 TABLE 439 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 320 TABLE 440 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 320 TABLE 441 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 321 TABLE 442 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 443 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 322 TABLE 444 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 322 TABLE 445 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 323 TABLE 446 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 324 TABLE 447 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 324 TABLE 448 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 324 TABLE 449 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 325 TABLE 450 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 325 TABLE 451 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 326 TABLE 452 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 326 TABLE 453 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 327 TABLE 454 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 327 TABLE 455 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023–2030 (USD MILLION) 328 TABLE 456 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 328 TABLE 457 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 329 TABLE 458 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023–2030 (USD MILLION) 329 TABLE 459 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 330 TABLE 460 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023–2030 (USD MILLION) 330 TABLE 461 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 331 TABLE 462 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET, JANUARY 2021−JUNE 2025 332 TABLE 463 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION 335 TABLE 464 INFECTIOUS DISEASE DIAGNOSTICS MARKET: REGION FOOTPRINT 339 TABLE 465 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 340 TABLE 466 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TYPE OF TESTING FOOTPRINT 340 TABLE 467 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT 341 TABLE 468 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 343 TABLE 469 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 343 TABLE 470 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 344 TABLE 471 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 346 TABLE 472 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JUNE 2025 347 TABLE 473 INFECTIOUS DISEASE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021– JUNE 2025 348 TABLE 474 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 349 TABLE 475 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 350 TABLE 476 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 353 TABLE 477 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−JUNE 2025 355 TABLE 478 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–JUNE 2025 355 TABLE 479 ABBOTT: COMPANY OVERVIEW 357 TABLE 480 ABBOTT: PRODUCTS/SERVICES OFFERED 358 TABLE 481 ABBOTT: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 360 TABLE 482 ABBOTT: DEALS, JANUARY 2021−JUNE 2025 361 TABLE 483 DANAHER CORPORATION: COMPANY OVERVIEW 362 TABLE 484 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 363 TABLE 485 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 365 TABLE 486 DANAHER CORPORATION: DEALS, JANUARY 2021–JUNE 2025 366 TABLE 487 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−JUNE 2025 367 TABLE 488 BIOMÉRIEUX: COMPANY OVERVIEW 368 TABLE 489 BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED 369 TABLE 490 BIOMÉRIEUX: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 373 TABLE 491 BIOMÉRIEUX: DEALS, JANUARY 2021– JUNE 2025 375 TABLE 492 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 377 TABLE 493 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 378 TABLE 494 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 380 TABLE 495 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JUNE 2025 381 TABLE 496 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 383 TABLE 497 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED 384 TABLE 498 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021–JUNE 2025 386 TABLE 499 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021−JUNE 2025 386 TABLE 500 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021−JUNE 2025 387 TABLE 501 HOLOGIC, INC.: COMPANY OVERVIEW 388 TABLE 502 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED 389 TABLE 503 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 390 TABLE 504 HOLOGIC, INC.: DEALS, JANUARY 2021– JUNE 2025 391 TABLE 505 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 392 TABLE 506 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED 393 TABLE 507 BECTON, DICKINSON AND COMPANY: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 396 TABLE 508 BD: DEALS, JANUARY 2021–JUNE 2025 397 TABLE 509 BD: EXPANSIONS, JANUARY 2021– JUNE 2025 398 TABLE 510 REVVITY, INC.: COMPANY OVERVIEW 399 TABLE 511 REVVITY, INC.: PRODUCTS/SERVICES OFFERED 400 TABLE 512 REVVITY INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 402 TABLE 513 QIAGEN N.V.: COMPANY OVERVIEW 403 TABLE 514 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED 404 TABLE 515 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 406 TABLE 516 QIAGEN N.V.: DEALS, JANUARY 2021–JUNE 2025 408 TABLE 517 QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JUNE 2025 408 TABLE 518 SEEGENE INC.: COMPANY OVERVIEW 409 TABLE 519 SEEGENE INC.: PRODUCTS/SERVICES OFFERED 410 TABLE 520 SEEGENE INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 411 TABLE 521 SEEGENE INC.: DEALS, JANUARY 2021– JUNE 2025 412 TABLE 522 SEEGENE INC.: EXPANSIONS, JANUARY 2021– JUNE 2025 413 TABLE 523 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 414 TABLE 524 GRIFOLS, S.A.: COMPANY OVERVIEW 416 TABLE 525 DIASORIN S.P.A.: COMPANY OVERVIEW 417 TABLE 526 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 419 TABLE 527 SYSMEX CORPORATION: COMPANY OVERVIEW 421 TABLE 528 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW 422 TABLE 529 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW 423 TABLE 530 SD BIOSENSOR, INC.: COMPANY OVERVIEW 424 TABLE 531 BIOSYNEX SA: COMPANY OVERVIEW 425 TABLE 532 TRINITY BIOTECH: COMPANY OVERVIEW 427 TABLE 533 BRUKER (ELITECHGROUP): COMPANY OVERVIEW 428 TABLE 534 GENETIC SIGNATURES: COMPANY OVERVIEW 430 TABLE 535 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW 430 TABLE 536 TRIVITRON HEALTHCARE: COMPANY OVERVIEW 431 TABLE 537 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW 432 TABLE 538 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW 433 TABLE 539 UNIOGEN OY: COMPANY OVERVIEW 434 TABLE 540 VELA DIAGNOSTICS: COMPANY OVERVIEW 435 TABLE 541 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW 436 FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE 40 FIGURE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 44 FIGURE 3 PRIMARY SOURCES 47 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 50 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 50 FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 51 FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS T 52 FIGURE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH 54 FIGURE 9 DATA TRIANGULATION METHODOLOGY 55 FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS 56 FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 58 FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION) 59 FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 59 FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 60 FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION) 61 FIGURE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION) 62 FIGURE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 62 FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 63 FIGURE 19 RISING FOCUS ON R&D FOR INFECTIOUS DISEASE DIAGNOSTICS TO PROPEL MARKET 64 FIGURE 20 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 65 FIGURE 21 LABORATORY TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 65 FIGURE 22 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 66 FIGURE 23 HEPATITIS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 66 FIGURE 24 IMMUNODIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 67 FIGURE 25 DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 67 FIGURE 26 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 68 FIGURE 27 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 68 FIGURE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 69 FIGURE 29 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2015–DECEMBER 2024) 79 FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 81 FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 83 FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 85 FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 86 FIGURE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 98 FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 99 FIGURE 36 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 99 FIGURE 37 NUMBER OF DEALS & FUNDING ACTIVITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 100 FIGURE 38 MARKET POTENTIAL OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 103 FIGURE 39 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 230 FIGURE 40 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 274 FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2022–2024) 334 FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2024) 335 FIGURE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 338 FIGURE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY FOOTPRINT 339 FIGURE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 342 FIGURE 46 EV/EBITDA OF KEY VENDORS 344 FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 345 FIGURE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS 346 FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 350 FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2024) 358 FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 363 FIGURE 52 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 369 FIGURE 53 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 378 FIGURE 54 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 384 FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 389 FIGURE 56 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024) 393 FIGURE 57 REVVITY, INC.: COMPANY SNAPSHOT (2024) 400 FIGURE 58 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 404 FIGURE 59 SEEGENE INC.: COMPANY SNAPSHOT (2024) 410

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們